Free Trial

UBS Group Has Lowered Expectations for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • UBS cut its DENTSPLY SIRONA price target from $17 to $13 but maintained a Buy rating; the new target implied 43.41% upside from the stock’s then-current price of $9.06.
  • Analyst sentiment was mixed: the consensus rating was “Reduce,” with an average price target of $12.08; three analysts rated the stock Buy, seven Hold and four Sell.
  • DENTSPLY SIRONA missed quarterly expectations, reporting EPS of $0.29 versus $0.31 expected and revenue of $836 million versus $861.68 million expected. Revenue was down 7.5% year over year.
  • Five stocks we like better than DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) had its target price decreased by investment analysts at UBS Group from $17.00 to $13.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. UBS Group's price target would indicate a potential upside of 43.41% from the stock's current price.

Several other equities analysts have also recently commented on XRAY. Barrington Research lowered their target price on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Monday, October 26th. BMO Capital Markets dropped their price target on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research report on Thursday, September 17th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research note on Friday, October 30th. Piper Sandler decreased their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Friday, October 9th. Finally, Bank of America reiterated a "buy" rating on shares of DENTSPLY SIRONA in a report on Friday, November 6th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average price target of $12.08.

Read Our Latest Analysis on DENTSPLY SIRONA

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY traded down $0.10 on Monday, reaching $9.06. 867,408 shares of the company's stock were exchanged, compared to its average volume of 4,928,026. The business's 50-day moving average is $9.43 and its two-hundred day moving average is $11.20. The company has a quick ratio of 1.04, a current ratio of 1.63 and a debt-to-equity ratio of 1.47. DENTSPLY SIRONA has a fifty-two week low of $8.14 and a fifty-two week high of $14.76. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -14.60, a PEG ratio of 1.34 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by ($0.02). The company had revenue of $836.00 million for the quarter, compared to analyst estimates of $861.68 million. DENTSPLY SIRONA had a negative net margin of 3.38% and a positive return on equity of 20.21%. The company's revenue for the quarter was down 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.37 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. As a group, equities research analysts forecast that DENTSPLY SIRONA will post 1.21 EPS for the current year.

Institutional Trading of DENTSPLY SIRONA

Institutional investors have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY bought a new stake in DENTSPLY SIRONA during the 2nd quarter worth about $39,775,000. BlackRock Inc. acquired a new stake in DENTSPLY SIRONA in the 2nd quarter valued at about $283,405,000. The Manufacturers Life Insurance Company acquired a new stake in DENTSPLY SIRONA in the 2nd quarter valued at about $1,956,000. Bank of New York Mellon Corp bought a new position in shares of DENTSPLY SIRONA in the second quarter worth about $16,408,000. Finally, Edmond DE Rothschild Holding S.A. bought a new position in shares of DENTSPLY SIRONA in the second quarter worth about $47,780,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

(Get Free Report)

DENTSPLY SIRONA Inc. develops, manufactures and markets products and technologies for dental professionals. Its portfolio includes dental equipment and imaging systems, digital dentistry and CAD/CAM solutions, dental implants, endodontic and restorative products, and supplies used in preventive care. The company serves dental practices, laboratories and other customers around the world. Its products support a range of clinical activities, including diagnosis, treatment planning, restorative dentistry and oral hygiene.

Further Reading

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DENTSPLY SIRONA Right Now?

Before you consider DENTSPLY SIRONA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.

While DENTSPLY SIRONA currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines